Miguel Ruão's research while affiliated with Centro Hospitalar de Entre o Douro e Vouga and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (8)
Purpose
Age-related macular degeneration (AMD) is one of the main causes of blindness and visual impairment worldwide. As achieving a dry macula is one of the main objectives in AMD management, the purpose of this work was to reach a consensus on the relevance of retinal fluid in function, disease activity control and treatment patterns.
Methods
F...
Aim:
To develop the first Ophthalmology joint guidelines with Paediatric Rheumatology with recommendations on the screening, monitoring and medical treatment of juvenile idiopathic arthritis-associated uveitis (JIA-U), endorsed by the Portuguese Society of Ophthalmology (SPO).
Methods:
A systematic literature review was conducted to include publ...
We present the case report of a 6-year-old girl with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis associated with bilateral optic neuritis. She initially presented with disturbing behaviors and gait impairments and was hospitalized in the context of meningoencephalitis, without agent isolation and with inconclusive laboratory tests....
Purpose:
The purpose of this study was to evaluate the 2-year outcome of ranibizumab for diabetic macular oedema (DME) in the real-life clinical practice of five ophthalmology departments of the National Health Service (NHS) in Portugal.
Methods:
This is a retrospective multicentre study. The clinical records on consecutive patients with DME fro...
Purpose
The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases.
Methods
Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hosp...
Purpose
To evaluate the prevalence of different optical coherence tomography (OCT) findings in European patients with high myopia.
Methods
Cross-sectional study conducted in the Macula Unit of the University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 134 myopic eyes of 69 patients (16 males and 53 females) were included. All pati...
Purpose
To report the experience of a single center in photoscreening 1-year-olds for amblyogenic risk factors over a 9-year period and to estimate amblyopia prevalence in this population.
Methods
The records of 11,029 children 11-18 months of age who were screened for amblyogenic risk factors at Centro Hospitalar de Entre o Douro e Vouga between...
Citations
... Several real-world studies on ranibizumab in DME have evaluated treatment patterns and outcomes over periods of 9 to 24 months. [22][23][24][25][26][27][28][29][30][31][32][33][34][35] Mean number of ranibizumab injections ranged from 3.1 to 7.2. VA gains varied between +0.0 and +8.4 letters with CRT reductions ranging from −83.9 µm to −164.6 µm. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272281440092166-1441928362205_Q64/Rufino-Silva.jpg)
... Bilateral same-day injections are safe, however, patient safety and medico-legal concerns persist. [24,25] We identified the procurement of the injection pack as an additional opportunity to reduce emissions. A survey of the clinicians performing the injections identified several items that were deemed to be safely dispensable from the intravitreal packs -these were: plastic tongs for betadine application, a 2 ml syringe, the hard outer plastic container, and the paper hand towel. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/578676590297088-1514978658159_Q64/Rosa-Dolz-Marco.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/277988429058048-1443289014261_Q64/Roberto-Gallego-Pinazo.jpg)
... PlusOptix 20,24,26,28,29 and SPOT 21,22,25,27,30 was the most used device, followed by MTI 18,23,28 and Retinomax. 19 One study 28 used an MTI in the first years of screening that was subsequently replaced by PlusOptix for the remaining period. ...
